Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Colvin

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Surgical Endoscopy|April 4, 2024
Society of American Gastrointestinal and Endoscopic Surgeons guidelines development: health equity update to standard operating procedureSunjay S Kumar, Amelia T Collings, Courtney Collins, et al.
Surgical Endoscopy|August 28, 2025
A SAGES guide to navigating a changing landscape and continuing to promote surgical excellence and opportunity for allJenny M Shao, Hope T Jackson, Andrew Schlussel, et al.
British Journal of Haematology|August 10, 2013
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomasAndrew M Evens, Steven T Rosen, Irene Helenowski, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Surgical Endoscopy|April 4, 2024
Society of American Gastrointestinal and Endoscopic Surgeons guidelines development: health equity update to standard operating procedureSunjay S Kumar, Amelia T Collings, Courtney Collins, et al.
Surgical Endoscopy|August 28, 2025
A SAGES guide to navigating a changing landscape and continuing to promote surgical excellence and opportunity for allJenny M Shao, Hope T Jackson, Andrew Schlussel, et al.
British Journal of Haematology|August 10, 2013
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomasAndrew M Evens, Steven T Rosen, Irene Helenowski, et al.
Pageof 2